Latest
Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Adolescent depression care widens past SSRI defaults
Esketamine adolescent indication consideration, ECT and TMS adolescent access, structured measurement-based care, and integrated school-and-medical models are reshaping adolescent depression care.
AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
By signal pillar
Clinical readouts
14Bispecific T-cell engager uptake in lymphoma is constrained by cytokine-release-syndrome management capacity
Bispecific T-cell engagers in B-cell lymphoma are demonstrating strong response rates in late-line settings, but commercial uptake is limited by the cytokine-release-syndrome management infrastructure required for safe administration. The constraint is more binding than the clinical evidence base suggests.
IPF antifibrotic class is evolving with second-generation mechanisms
Idiopathic pulmonary fibrosis treatment has been defined by the two approved antifibrotics (pirfenidone, nintedanib) for a decade. The second-generation pipeline is now reading out, with mechanisms targeting different points in the fibrotic pathway and the potential to combine with the established class.
KRAS G12C resistance patterns are reshaping second-line NSCLC sequencing
Resistance mechanisms emerging from sotorasib and adagrasib post-progression sampling are converging on a finite set of pathways. The implications for second-line decision-making and combination design are starting to land in clinic.
TROP2 ADC class read-throughs from Q1 2026 readouts
The TROP2 antibody-drug conjugate class has multiple late-stage assets reading out in overlapping breast cancer and NSCLC populations. Q1 2026 readouts have started to differentiate the class on toxicity profile and biomarker dependency rather than on bulk efficacy.
Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
Non-hormonal vasomotor symptom options are now in routine use
Fezolinetant uptake has been faster than analyst projections, and the field is now in the post-launch phase where prescribing patterns, payer coverage, and longer real-world safety data shape adoption.
Psychedelic-assisted therapy: clinical pipeline progress, regulatory caution
MDMA- and psilocybin-based therapies have advanced through late-stage trials, but the FDA's measured response - and the system requirements those therapies impose on delivery - mean rollout will be slower and more constrained than mechanism enthusiasm suggested.
Severe asthma biologics: which patients are still being left out?
Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.
The "clinically meaningful" debate around CDR-SB is not settling
The interpretive argument over whether a sub-half-point CDR-SB delta represents a clinically meaningful slowing of decline continues to shape regulatory, payer, and clinician views.
Donanemab introduces a finite-duration treatment model
Donanemab's protocol allows treatment cessation once amyloid plaque clearance is confirmed - a meaningfully different model from indefinite biologic dosing.
APOE4 genotype is reshaping eligibility, dosing, and disclosure
Anti-amyloid trial readouts and post-marketing surveillance both show APOE4 homozygotes face higher ARIA risk - pushing genotype testing into pre-treatment workflows.
GLP-1 receptor agonists enter Alzheimer's clinical trials
Phase 3 readouts on semaglutide in Alzheimer's are due, with mechanistic interest in metabolic, vascular, and inflammatory pathways.
Subcutaneous anti-amyloid formulations move toward filing
Subcutaneous lecanemab data has been submitted to regulators; subcutaneous donanemab is in late development. Both reframe the access question.
Tau-targeting programs advance behind the amyloid wave
Anti-tau immunotherapies and small molecules are progressing through mid-stage trials, with the field watching for the first credible clinical signal.
Regulatory
8FDA approves leucovorin calcium as first treatment for CFD-FOLR1
The FDA has approved expanded use of Wellcovorin (leucovorin calcium) tablets for cerebral folate deficiency caused by confirmed FOLR1 gene variants, marking the first approved treatment for this rare neurological condition in adults and children.
FDA approves tividenofusp alfa for neurologic Hunter syndrome
The FDA approved Avlayah (tividenofusp alfa-eknm) to treat the neurologic manifestations of MPS II (Hunter syndrome), marking the first therapy specifically indicated for the CNS dimension of this rare lysosomal storage disorder.
FDA approves first gene therapy for severe LAD-I
The FDA approved Kresladi (marnetegragene autotemcel), the first gene therapy indicated for severe Leukocyte Adhesion Deficiency Type I, marking the first approved treatment specifically targeting the genetic root cause of this rare, life-threatening immune disorder.
FDA accelerated-approval reform is changing oncology evidence requirements
Post-Aduhelm reform of the accelerated-approval pathway has tightened expectations for confirmatory trial design, enrolment timing, and surrogate-endpoint validity. Oncology programs targeting accelerated approval are seeing the practical effect first.
JAK class label restrictions are reshaping moderate-disease prescribing
FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.
Newborn screening expansion is uneven across US states
RUSP additions tell only half the story - state-level implementation timelines stretch the diagnostic-to-treatment gap, and the variation has consequences for treatment-eligibility windows in time-sensitive rare disease.
NICE keeps the UK out of step with US and EU on anti-amyloid coverage
NICE's negative cost-effectiveness opinion on lecanemab and donanemab leaves the UK as a meaningful policy outlier, even after MHRA authorization.
FDA's accelerated approval pathway under continued post-Aduhelm scrutiny
Aducanumab's voluntary withdrawal in 2024 left lasting institutional caution about surrogate-endpoint approvals in neurodegeneration.
Market access & reimbursement
9NICE's rejection of lecanemab and donanemab is widening the transatlantic access gap
Final NICE guidance declined both anti-amyloid antibodies for routine NHS use on cost-effectiveness grounds. The same products are reimbursed in Germany and approved (with payer fragmentation) in the US. The bifurcation is hardening rather than resolving.
Donanemab's limited-duration treatment paradigm is reshaping the lifetime cost calculation against lecanemab
Donanemab's protocol stops dosing once amyloid clearance is achieved, typically 12-18 months. Lecanemab is continuous indefinitely. Over a 10-year treatment horizon, the implied lifetime cost difference is substantial.
Anti-VEGF biosimilar uptake is reshaping retinal commercial dynamics
Anti-VEGF biosimilars (ranibizumab and aflibercept biosimilars) entering the retinal market in major geographies are reshaping commercial dynamics for the established class and for the next-generation extended-duration retinal pipeline. The implications across the wet AMD, DME and adjacent indications are material.
PARP inhibitors in ovarian cancer maintenance are facing access pressure
Real-world ovarian cancer PARP maintenance use across major markets shows access pressure: prior-authorisation criteria tightening, payer-side post-marketing evidence demands, and ongoing reassessment of the eligible-population framing.
NICE rare-disease modifier consultation is reshaping HTA for ultra-rare therapies
NICE's consultation on the severity modifier and the rare-disease threshold has substantive implications for ultra-rare therapy access in England. The submitted consultation responses are diverging on the question of whether the threshold should be retained, reframed or removed.
EU market-access pathway for BCMA bispecifics is bifurcating
Coverage decisions across the major EU markets for the BCMA bispecific class in relapsed-refractory multiple myeloma are diverging on use-setting, prior-line requirements, and post-marketing evidence demands. The variance is wider than the underlying clinical evidence supports.
GLP-1 supply is normalising; access still depends on indication
Manufacturing capacity expansion has eased the chronic supply shortfall that defined 2023-24, but reimbursement variation by indication - obesity vs diabetes vs cardiovascular risk reduction - continues to define who can actually start therapy.
Tau PET reimbursement is the next diagnostic access question
Amyloid PET has settled into routine coverage and availability. Tau PET - which will be the confirmatory pathway for tau-directed therapies - is sited at meaningfully fewer centers and reimbursed unevenly. The access conversation that defined anti-amyloid rollout is about to repeat, one mechanism later.
Commercial payer coverage of anti-amyloid therapy is diverging from Medicare
Commercial payers are setting prior authorization and step-therapy criteria that meaningfully diverge from Medicare's coverage-with-evidence-development frame.
Policy & system
3UK newborn screening expansion proposal would change the rare-disease patient-finding model
The UK National Screening Committee's proposed expansion of the newborn blood-spot screening panel to additional rare conditions has implications for diagnosis timing, treatment-eligible patient identification, and commercial planning for orphan therapies in those conditions.
Caregiver support is becoming part of the Alzheimer's policy frame
CMS's GUIDE Model and adjacent caregiver-support policy are reshaping how dementia care is paid for outside the medication and diagnostic frame.
Medicare's coverage-with-evidence-development decision still shapes the rollout
The CMS coverage framework requiring registry participation has had measurable effects on which sites prescribe and where patients get treated.
Scientific
144Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Adolescent depression care widens past SSRI defaults
Esketamine adolescent indication consideration, ECT and TMS adolescent access, structured measurement-based care, and integrated school-and-medical models are reshaping adolescent depression care.
AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Thyroid disease in pregnancy management formalises around structured monitoring
Pregnancy-specific TSH targets, structured pre-conception thyroid management, and integrated maternal-fetal medicine and endocrinology pathways are reshaping thyroid disease in pregnancy.
Treatment-resistant schizophrenia care formalises around clozapine integration
Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.
IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Frontotemporal dementia therapy programs reach late-stage trials
Progranulin-replacement therapy in GRN-mutation FTD, ASO programs in C9orf72 FTD-ALS, and tau-targeted programs are emerging in a previously bare category.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Osteogenesis imperfecta therapy reshapes around anti-sclerostin programs
Setrusumab pivotal data, bisphosphonate maturity, and emerging gene therapy programs are reshaping osteogenesis imperfecta management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Achondroplasia therapy options widen past vosoritide
Vosoritide commercial maturity and follow-on CNP analogue and FGFR3-targeted programs are restructuring achondroplasia management.
Dementia with Lewy bodies care formalises around alpha-synuclein-aware management
Cholinesterase inhibitor optimisation, antipsychotic-avoidance protocols, RBD recognition pathways, and emerging alpha-synuclein-targeted programs are reshaping DLB care.
CIDP therapy reshapes around FcRn antagonist class entry
Efgartigimod CIDP indication, follow-on FcRn antagonist programs, and structured maintenance protocols are reshaping chronic inflammatory demyelinating polyneuropathy management.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Congenital adrenal hyperplasia therapy reshapes around CRF1 receptor antagonism
Crinecerfont approval, follow-on CRF1 receptor antagonist programs, and structured care infrastructure are reshaping classic congenital adrenal hyperplasia management.
Autism spectrum disorder pharmacotherapy options widen past irritability indications
Risperidone and aripiprazole maturity for ASD-associated irritability, emerging mechanism-targeted programs for core symptoms, and integrated multidisciplinary care models are reshaping ASD pharmacotherapy.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
Phenylketonuria therapy options mature past low-phenylalanine diet
Pegvaliase commercial maturity, sapropterin use, and emerging gene therapy programs are restructuring phenylketonuria management.
Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Pelvic floor disorder therapy options widen past Kegel-and-surgery defaults
Pelvic floor physiotherapy formalisation, vibegron and emerging beta-3 agonist programs in overactive bladder, and integrated multidisciplinary care models are reshaping pelvic floor disorders.
Chronic neuropathic pain therapy reshapes around novel sodium channel mechanisms
Suzetrigine (Nav1.8 inhibitor) acute pain approval and follow-on Nav1.8 and Nav1.7 programs in chronic pain are reshaping non-opioid pain management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Neuromyelitis optica spectrum disorder therapy class competition matures
Eculizumab, ravulizumab, satralizumab, inebilizumab, and emerging mechanism programs define a competitive NMOSD prescribing landscape.
Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Spinal muscular atrophy long-term outcome data reshapes treatment expectations
Multi-year outcome data across nusinersen, onasemnogene abeparvovec, and risdiplam plus emerging combination strategies are clarifying long-term SMA treatment expectations.
Chimeric autoantibody receptor T cells enter pemphigus vulgaris
Desmoglein 3-targeted CAART cell therapy programs in pemphigus vulgaris are reading out as a precision approach to autoantibody-driven disease.
Restless legs syndrome therapy reshapes around augmentation avoidance
Alpha-2-delta ligand first-line preference, low-dose opioid use, and novel mechanism programs are restructuring restless legs syndrome management.
Post-stroke spasticity therapy options widen past oral baclofen
Botulinum toxin maturity, intrathecal baclofen pump access, and emerging novel mechanism programs are reshaping post-stroke spasticity management.
Breast cancer survivorship care widens past tamoxifen and aromatase inhibitor side-effect management
Vasomotor symptom therapy in breast cancer survivors, bone-health management with aromatase inhibitors, and structured survivorship programs are reshaping breast cancer survivorship care.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Heart failure with reduced ejection fraction therapy moves beyond four-pillar standard
Vericiguat addition, mechanism-targeted programs, and emerging genetically-defined HFrEF approaches are reshaping the post-four-pillar landscape.
Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD
Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.
Insomnia comorbid with mental health conditions acquires structured therapy options
Daridorexant maturity, cognitive-behavioural therapy for insomnia (CBT-I) digital expansion, and integrated mental-health-and-insomnia treatment models are reshaping comorbid insomnia care.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Keratoconus therapy widens past corneal cross-linking
Corneal cross-linking adoption, intracorneal ring segment maturity, and emerging custom cross-linking and topography-guided treatment are reshaping keratoconus management.
Hemophilia gene therapy real-world data starts to clarify durability
Approved factor VIII and factor IX gene therapy products are accumulating real-world durability data that defines the addressable-population reality.
Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Stroke prevention restructures across atrial fibrillation, lipids, and acute window
Factor XIa inhibitors entering late-stage trials, expanded thrombectomy windows, and tenecteplase displacement of alteplase are restructuring stroke prevention and acute care.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Pre-eclampsia prediction and prevention infrastructure matures
sFlt-1 to PlGF ratio testing in suspected pre-eclampsia and aspirin-prophylaxis pathway adoption are reshaping pre-eclampsia care.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Dementia behavioural symptoms acquire approved pharmacotherapy
Brexpiprazole approval for agitation in Alzheimer's dementia and follow-on programs are reshaping dementia behavioural symptom management.
Thyroid eye disease therapy grows past teprotumumab
Teprotumumab maturity plus follow-on IGF-1R-targeted programs and novel non-IGF-1R mechanism classes are restructuring thyroid eye disease management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Hereditary angioedema oral options reach maturity
Oral plasma kallikrein inhibitors and emerging factor XIIa inhibitor programs are restructuring HAE prophylaxis and on-demand therapy.
Diabetic peripheral neuropathy therapy advances after a long quiet period
Capsaicin patch maturity, novel sodium channel modulators, and emerging disease-modifying programs are reshaping diabetic peripheral neuropathy management.
Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
Inherited retinal disease gene therapy widens past RPE65
X-linked retinitis pigmentosa, choroideremia, and additional inherited retinal disease gene therapy programs are reading out.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Sarcoidosis acquires mechanism-targeted therapy after a long quiet period
Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.
Obsessive-compulsive disorder modern options mature
Deep brain stimulation maturity, novel glutamate-modulator programs, and refined transcranial magnetic stimulation protocols are reshaping refractory OCD management.
Genetically-targeted Parkinson's programs reach pivotal data
LRRK2 inhibitors and GBA-targeted programs in Parkinson's disease are reading out as the first genetically-defined Parkinson's therapy options.
OCD and intractable-condition options widen
Deep brain stimulation, transcranial magnetic stimulation, and emerging psychedelic-assisted therapy are all reaching into refractory OCD.
Tumor-infiltrating lymphocyte therapy expands past melanoma
TIL therapy approval in metastatic melanoma is opening pathways into cervical and other solid tumour indications.
Fertility therapy moves from procedural to pharmacological
Pharmacological adjuncts and oocyte-quality interventions are expanding the fertility-therapy toolset beyond the IVF procedural footprint.
Tardive dyskinesia therapy access patterns
Approved VMAT2 inhibitor therapy for tardive dyskinesia continues to expand but underdiagnosis remains the primary gap.
Vaping-associated lung disease as a recognised category
EVALI (e-cigarette and vaping-associated lung injury) and chronic bronchiolitis from vaping are now recognised pulmonology diagnostic categories.
Cell therapy moves into non-malignant rare disease
Cell-therapy approaches are beginning to land in non-malignant rare-disease indications including severe lupus, scleroderma, and inherited metabolic conditions.
UK menopause therapy positioning shifts
MHRA approvals and NICE guidance on non-hormonal vasomotor agents are reshaping the UK menopause-therapy framing.
Concussion and TBI biomarker tools mature
Plasma GFAP and UCH-L1 assays for concussion and traumatic brain injury are establishing routine emergency-department use.
Choroidal melanoma therapy options widen
Approved tebentafusp and emerging programs are creating the first systemic therapy options for metastatic choroidal melanoma.
PAH combination therapy moves to first-line
Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.
Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Apolipoprotein C3-targeted therapy expands lipid management
ApoC3-targeted programs are widening the triglyceride-lowering toolset and entering routine lipid practice.
Infant RSV monoclonal antibody enters routine birth pathways
Long-acting RSV monoclonal antibody is becoming part of routine newborn care across high-income systems.
Rapid-onset depression therapy reshapes the field
Esketamine, oral postpartum depression therapy, and pipeline rapid-acting agents are changing the timing assumption built into depression care.
IL-23 dominance in psoriasis settles in
IL-23 inhibitors have become the default systemic option for moderate-to-severe psoriasis, leaving IL-17 and TNF in second-line slots.
Non-hormonal contraception finally moves
After decades of incremental progress, novel non-hormonal contraceptive mechanisms are entering pivotal trials and early-launch markets.
Progressive MS as the open question
Therapy for relapsing MS is mature; primary and secondary progressive disease remains the unsolved problem.
Adult RSV vaccination's slow-build season
Adult RSV vaccination programs are entering their second and third seasons - real-world uptake is the test.
Continuous glucose monitoring goes mainstream
Continuous glucose monitoring is expanding beyond type 1 diabetes into type 2 management and even non-diabetic wellness use.
Eosinophilic esophagitis as a real prescribing category
Approved biologic therapy for eosinophilic esophagitis has turned a long-overlooked condition into a defined prescribing category.
Atopic dermatitis: a crowded biologic field finds its tiers
Multiple biologic and oral options in atopic dermatitis are sorting into clinical tiers based on response durability and safety.
Bispecifics reshape relapsed lymphoma care
T-cell engaging bispecifics are settling into routine third-line and later care for diffuse large B-cell and follicular lymphoma.
Lipoprotein(a) emerges as a treatable target
Late-stage Lp(a)-lowering programs may close one of cardiovascular medicine's longest-standing risk-factor gaps.
Diabetic eye disease as a screening problem
Therapy for diabetic retinopathy and macular edema is well-established; the operational story is whether at-risk patients get screened in time.
Plasma biomarker testing is displacing amyloid PET as the screening modality for anti-amyloid eligibility
Three FDA-cleared blood tests for amyloid pathology are now in routine use at major Alzheimer's centres, materially reducing the amyloid-PET demand that constrained early lecanemab uptake.
Durable anti-VEGF and the injection burden problem
Longer-acting anti-VEGF agents are reframing how routine retinal-disease maintenance gets delivered.
Radioligand therapy as a routine oncology option
Targeted radioligand therapy is settling into prostate and neuroendocrine cancer treatment as a routine, infrastructure-bound modality.
APOL1-targeted therapy and the precision-nephrology turn
Targeted therapy for APOL1-mediated kidney disease marks the first precision-nephrology category in routine practice.
Advanced delivery options in Parkinson's
Subcutaneous levodopa, deep brain stimulation, and continuous infusion are reshaping how advanced Parkinson's disease is managed.
Long-acting HIV prevention enters routine care
Long-acting injectable HIV prevention is establishing itself alongside daily oral regimens.
CGRP therapy normalises in migraine care
CGRP-class agents have moved from specialty curiosity to routine migraine prevention and acute treatment.
ASO platform diversification beyond DMD is reshaping rare-disease commercial planning
The antisense oligonucleotide (ASO) platform has moved beyond the DMD foundation into multiple rare-disease indications including SMA, AdLD, Stargardt disease and adjacent conditions. The platform-level commercial logic is reshaping rare-disease portfolio strategy at multiple sponsors.
PROTAC oncology pipeline is transitioning from concept to commercial reality
Targeted protein degradation programs (PROTACs and molecular glues) in oncology have moved from early-stage proof-of-concept to multiple late-stage assets with pivotal readouts in the next 24 months. The mechanism's promise of drugging previously undruggable targets is closer to commercial validation than at any prior point.
Gantenerumab post-mortem: what the failure tells the field about Abeta-targeting
The gantenerumab phase 3 readout failure is a useful data point for understanding what differentiates the successful anti-amyloid antibody class from the unsuccessful programs. The implications for next-generation amyloid-targeting and adjacent neurodegeneration pipeline are material.
Schizophrenia pipeline shifts from D2 to muscarinic mechanisms
The schizophrenia therapeutic pipeline is shifting from the dopamine D2 receptor mechanism that has defined antipsychotic therapy for fifty years toward muscarinic receptor mechanisms with substantively different efficacy and tolerability profiles. The implications for the schizophrenia commercial category are material.
Parkinson's biomarker work is converging on the alpha-synuclein seed-amplification assay
The alpha-synuclein seed-amplification assay (alpha-syn-SAA) has emerged as the leading biomarker for Parkinson's disease and adjacent synucleinopathies. The assay's sensitivity, specificity, and the implications for both diagnosis and trial-enrolment are material.
Antibody-drug conjugates as a routine option
ADC-class therapies are normalising into solid-tumour treatment plans across breast, lung, and bladder cancer.
Obesity recognised as a metabolic disease
Coverage decisions and treatment guidelines are catching up with the framing of obesity as a chronic, treatable disease.
JAK inhibitors find their tier
Oral JAK inhibitors are settling into a defined tier across rheumatology, IBD, and dermatology after several years of label and safety recalibration.
Newborn screening expands the rare-disease frontier
The expanding newborn-screening panel is changing when and how rare diseases are identified - and what therapy that opens up.
Bispecifics expanding the oncology toolkit
T-cell engagers and bispecific antibodies continue to broaden the oncology toolkit across haematological and solid tumours.
GLP-1 as a metabolic platform
Single, dual, and triple agonists are extending GLP-1 therapy beyond diabetes into obesity, cardiovascular, renal, and emerging neurodegenerative use.
Quadruple therapy in heart failure
Heart-failure-with-reduced-ejection-fraction care has settled around four-pillar therapy; the question is whether routine practice keeps up.
Co-pathology recognition is reshaping how Alzheimer's diagnosis is being read
LATE, vascular contribution, and Lewy-body co-pathology are now routinely on the differential when a patient with cognitive symptoms tests amyloid-positive. The clinical question is increasingly "what mix" rather than "is it Alzheimer's."
IL-class biologics rebalancing immunology
IL-23 and IL-17 agents continue to take share from TNF inhibitors across rheumatology, IBD, and dermatology.
Biologics arrive in COPD
COPD is moving from a small-molecule-only category to one with biologic options for selected phenotypes.
Alopecia areata becomes a real category
Approved JAK inhibitors have turned alopecia areata into an actual prescribing category.
Parkinson's disease-modifying programs in motion
Multiple late-stage programs are testing whether Parkinson's disease modification can be demonstrated.
IBD targets move beyond TNF
IL-23, S1P modulators, and oral options are reshaping inflammatory bowel disease therapy choice.
Smouldering MS as the new frontier
Beyond relapses, smouldering disease is increasingly the lens through which MS therapy is judged.
Schizophrenia gets a new mechanism class
Muscarinic agonists and other novel mechanisms are entering schizophrenia care after decades of dopamine-class dominance.
Endometriosis: from chronic underdiagnosis to category formation
Diagnostic delay has historically defined endometriosis. New therapeutic and screening activity is reshaping that picture.
Rare-disease gene therapy after the first wave
After the first wave of approvals, the durability and access questions around rare-disease gene therapy are coming into focus.
Sickle cell gene therapy: science vs access
Approved gene therapies for sickle cell disease have created a new test of how access works for one-time, high-cost therapy.
Blood-based biomarkers move from research to clinical workflow
Plasma p-tau217 assays are being adopted as a triage step before PET or CSF confirmation in specialty memory clinics.
Geographic atrophy: a slow-build category
Geographic atrophy therapies are establishing themselves as a routine retinal care category.
AI in routine ophthalmology diagnostics
AI-assisted retinal imaging and triage tools are quietly becoming part of routine workflow in ophthalmology.
Severe asthma in the biologic era
Five biologic options later, the question in severe asthma is increasingly about phenotyping and switching.
Lipid management gets a new tier
PCSK9 inhibitors, lp(a)-targeted therapy, and inclisiran are rebuilding the cardiovascular prevention stack.
Dermatology's shift from topical to systemic
Atopic dermatitis, psoriasis, and alopecia are moving from topical and steroid mainstays to systemic biologic and small-molecule therapy.
MASH becomes a real prescribing category
After years of failed programs, metabolic dysfunction-associated steatohepatitis has its first approved therapies.
Treatment-resistant depression's expanding options
Esketamine, psilocybin programs, and rTMS are reshaping how treatment-resistant depression is managed.
Non-opioid analgesia after the rebalance
Novel sodium-channel modulators and other non-opioid mechanisms are entering acute and chronic pain care.
Antimicrobial resistance and the antibiotic gap
Antimicrobial resistance remains the slow-burn infectious-disease story without a sustained commercial answer.
Menopause therapy gets the investment cycle it was owed
Menopause therapy is finally seeing the development and investment activity that women's-health advocates have called for.
CKD therapy stack rebuilt
SGLT2 inhibitors, finerenone, and GLP-1 mechanisms are rebuilding the chronic-kidney-disease therapy stack.
Cell therapy as routine haematology
CAR-T and other cell therapies are normalising into haematology practice.
mRNA vaccines beyond the pandemic
mRNA platforms are extending into RSV, influenza, and adult vaccination programs.
Decentralised trials and the rare-disease infrastructure
Software-as-a-medical-device, in-vitro diagnostics, and decentralised trial infrastructure are reshaping how rare-disease therapy gets developed and delivered.
Alzheimer's: still watching the pipeline
Anti-amyloid therapy is now a routine option in selected patients; the next mechanism class is the open question.
Real-world evidence
21ARIA monitoring infrastructure is the rate-limit on anti-amyloid uptake
Centres prescribing lecanemab and donanemab consistently report that MRI surveillance capacity, not patient demand or insurance approval, is the bottleneck on how many patients they can treat in 2026.
Uterine fibroid GnRH antagonist combination therapy is displacing surgical-only management
GnRH antagonist combination therapy (with add-back hormone) for uterine fibroids has expanded medical management options for a condition that was historically managed primarily through surgery. The commercial implications across surgical referral patterns, fertility-preservation framing, and adjacent gynaecological pipeline are material.
Adult ADHD prescribing patterns are being reshaped by stimulant supply normalisation
The acute stimulant supply shortages that characterised 2022 to 2024 in adult ADHD are normalising. Prescribing patterns are stabilising at higher absolute levels than pre-shortage, with implications for both the established stimulant class and the non-stimulant pipeline.
ATTR amyloidosis silencer therapy uptake is transforming a previously underdiagnosed condition
Transthyretin amyloid cardiomyopathy (ATTR-CM) was historically underdiagnosed and undertreated. Approved silencer therapies (siRNA, ASO) and TTR stabilisers have moved the field rapidly, and the diagnostic-pathway access remains the rate-limit on commercial uptake.
Glaucoma drug-delivery implant uptake reveals the procedure-room workflow constraint
Sustained-release glaucoma drug-delivery implants are addressing the chronic adherence problem that has characterised glaucoma management for decades. Real-world uptake reveals the procedure-room workflow as the principal access constraint.
Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia
Real-world uptake of long-acting injectable (LAI) antipsychotics in schizophrenia is well below the eligible-population estimate across major markets, despite strong adherence and outcome benefits. The drivers are access infrastructure, prescriber inertia, and patient-pathway operational complexity.
Tezepelumab uptake in type-2-low severe asthma is the field's defining commercial test
Tezepelumab's upstream mechanism (anti-TSLP) reaches patients in the type-2-low phenotype that the downstream biologic class cannot effectively serve. Real-world commercial uptake in this previously underserved population is the test of whether the upstream-mechanism advantage translates from clinical evidence to commercial reality.
TYK2 inhibitor commercial uptake in psoriasis is reshaping the oral-versus-injection conversation
TYK2 inhibitor uptake in psoriasis is establishing the first commercially meaningful oral biologic alternative for moderate-to-severe disease. The route-of-administration conversation is now active in a way it has not been in the IL-23 and IL-17 era.
Hypertension treatment intensification gap remains the underdeveloped commercial opportunity
Real-world hypertension control rates across major markets remain substantially below guideline targets, with the treatment-intensification gap (patients on suboptimal regimens not advanced to combination or specialist therapy) as the principal driver. The commercial opportunity in closing this gap is large and is being addressed by combination-therapy programs and by emerging novel mechanisms.
Diabetic macular oedema commercial dynamics are being reshaped by the long-duration anti-VEGF class
The long-duration anti-VEGF class (faricimab, high-dose aflibercept) is reshaping diabetic macular oedema commercial dynamics through extended dosing intervals that reduce patient burden. The implications for the established anti-VEGF class, the steroid implant alternatives, and the adjacent retinal pipeline are material.
IBD biologic sequencing patterns reveal the early-line ustekinumab opportunity
Real-world IBD biologic sequencing data shows ustekinumab and adjacent IL-12/23 mechanisms moving earlier in the line of therapy than the historical anti-TNF-first paradigm. The implications for commercial planning across the IBD biologic class are material.
Postpartum depression novel mechanism uptake reveals the maternal-mental-health access gap
The approval of zuranolone for postpartum depression introduced a rapid-acting oral mechanism into a previously underserved indication. Real-world uptake patterns reveal the structural access gap in maternal mental health, with material implications for the commercial trajectory of adjacent maternal mental health pipeline.
Sickle cell disease curative therapy uptake exposes the conditioning-regimen access gap
Approved curative therapies for sickle cell disease (lentiviral gene therapy and CRISPR-edited autologous stem-cell therapy) are facing real-world uptake constrained by the conditioning regimen requirements and the specialist-centre infrastructure for autologous cell therapy.
Geographic atrophy therapy uptake reveals the disease-monitoring infrastructure gap
Real-world uptake of complement C3 and C5 inhibitors for geographic atrophy has been slower and more variable than the pivotal trial benefit profile would have predicted. The drivers are disease-monitoring infrastructure, intravitreal-injection capacity, and the patient-and-clinician decision frame around a slowly progressive condition.
COPD triple-therapy uptake remains uneven across markets
Single-inhaler triple therapy in COPD is the guideline-supported regimen for the eligible population, but real-world uptake remains uneven across major markets driven by step-therapy protocols, prescriber inertia, and access geography.
Finerenone CKD uptake reveals the cardio-renal-metabolic prescribing gap
Real-world finerenone uptake in chronic kidney disease patients with type 2 diabetes has been slower than the pivotal trial benefit profile would predict. The drivers are specialist coordination across cardiology, nephrology and endocrinology, and the operational complexity of integrating finerenone into existing regimens.
Menopause prescribing patterns are normalising after a decade of post-WHI under-treatment
Hormone therapy and non-hormonal vasomotor symptom prescribing patterns are normalising across major markets, reflecting accumulating real-world safety evidence and the emergence of non-hormonal mechanisms. The commercial category that the post-WHI period suppressed is being rebuilt.
Friedreich's ataxia real-world treatment uptake reveals the access-versus-efficacy gap
Real-world uptake of the first approved disease-modifying therapy for Friedreich's ataxia has been slower and more uneven than the pivotal trial population would have predicted. The drivers are infrastructure, payer behaviour, and patient-specialist matching, not the underlying clinical evidence.
Real-world ARIA rates from registries are landing close to trial estimates
Early registry data on lecanemab and donanemab in routine clinical use is producing ARIA incidence numbers that broadly track the pivotal trials, with APOE4 homozygotes consistently the highest-risk group.
Plasma-biomarker rollout is concentrated at academic centers
Adoption of plasma p-tau217 testing remains concentrated at academic medical centers and large specialty practices, with community uptake meaningfully behind.
Lecanemab uptake constrained by infusion infrastructure, not demand
Real-world rollout of lecanemab is gated by infusion-chair capacity and MRI monitoring schedules - not by patient interest or prescriber willingness.
Safety
1Manufacturing & supply
2GLP-1 supply normalisation is shifting the prescribing decision back to clinical fit
Manufacturing capacity for the GLP-1 class has substantially normalised after two years of supply constraint. The prescribing decision is moving back from availability-driven to clinical-fit-driven, and the commercial dynamics are shifting accordingly.
AAV gene-therapy manufacturing capacity remains the rate-limit on commercial uptake
The AAV gene-therapy class continues to face manufacturing-capacity constraints that limit commercial scale, particularly for high-dose indications. Investment in capacity is happening, but the lead times are long and the implications for commercial uptake are persisting longer than the field expected.